Non-interventional study to capture data on the use of a VWF/FVIII concentrate (wilate®) in all clinical settings of von Willebrand disease including health-related quality of life
[Translation] A prospective clinical study to evaluate the clinical efficacy, immunogenicity, pharmacokinetics and safety of human recombinant factor VIII in Chinese patients with severe hemophilia A
To evaluate the clinical efficacy of Human-cl rhFVIII in the prevention and treatment of bleeding events (BE). To define pharmacokinetic characteristics, determine incremental in vivo recovery - at study entry and over time, investigate potential immunogenicity, evaluate the efficacy of Human-cl rhFVIII as a surgical prophylaxis, and assess safety.
Prevention of bleeding in haemophilia A by prophylactic treatment with Octanate®, Wilate®, Nuwiq®: a prospective, multi-national, non-interventional study to evaluate routine practice prophylactic treatment schedules – NIS-Previq
100 Clinical Results associated with Octapharma Gmbh
Login to view more data
0 Patents (Medical) associated with Octapharma Gmbh
Login to view more data
10
Literatures (Medical) associated with Octapharma Gmbh
01 Feb 2023·GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark
A snapshot analysis of a prospective, non-interventional study to evaluate real-life prophylactic treatment schedules of factor VIII concentrates
Author: Oldenburg, J ; Wenning, S ; Seeger, S ; Feddern, J ; Halimeh, S ; Behnisch, W ; Klamroth, R ; Escuriola, C
01 Feb 2019·Science meets clinical practice
Haemophilia A Prophylaxis with FVIII in Real-life: Snapshot Analysis on the Observational Study “Prevention of Bleeding in Haemophilia A by Prophylactic Treatment with Octanate®, Wilate® or Nuwiq® - NIS Previq”
Author: Klamroth, R. ; Seeger, S. ; Wenning, S. ; Feddern, J. ; Scholz, U. ; Huth-Kühne, A. ; Escuriola-Ettingshausen, C. ; Oldenburg, J. ; Halimeh, S.
01 Feb 2019·Science meets clinical practice
Interim Results of a Non-interventional Study on Efficacy and Tolerability of a VWF/FVIII Concentrate in von Willebrand's Disease
Author: Kadar, J. ; Alesci, S. ; Lang, T. ; Rieke, M. ; Halimeh, S. ; Seeger, S. ; Koscielny, J. ; Feddern, J. ; von Depka, M. ; Daoud, M. ; Dempfle, C.-E.
100 Deals associated with Octapharma Gmbh
Login to view more data
100 Translational Medicine associated with Octapharma Gmbh
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.